Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccine immunogenicity in frail versus non-frail older Dutch adults
NL-OMON52138Phase 4Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Sep 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of 23-valent pneumococcal polysaccharide vaccine, influenza vaccine and SARS-CoV-2 vaccine in pneumococcal disease, influenza and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Primary antibody response to PPV23 and influenza vaccination. Started Sep 2020; status: active, not recruiting.
02
Drugs
23-valent pneumococcal polysaccharide vaccineinfluenza vaccineSARS-CoV-2 vaccine
03
Conditions
pneumococcal diseaseinfluenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON52138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52138.